Kinase inhibitors {#S0001}
=================

Vemurafenib is a selective BRAF inhibitor. Recently it has been evaluated in metastatic melanoma patients with BRAF V600E mutation after progression of earlier systemic treatment (phase 2 trial BRIM2). Vemurafenib was also tested in a phase 3 trial (BRIM3) in previously untreated patients. The results of these two trials led to its approval by the U.S. Food and Drug Administration (FDA) in August 2011 and the European Medicines Agency (EMA) in February 2012 for the treatment of metastatic melanoma with BRAF mutation. Updated overall survival (OS) results of the BRIM3 study have been presented at the ASCO meeting this year. The overall response rate in patients treated with vemurafenib was 57% \[5.6% -- complete response (CR), 51.3 -- partial response (PR)\] compared with 8.6% (1.2% -- CR, 7.4% -- PR) observed in patients receiving dacarbazine (DTIC). Median progression-free survival (PFS) was also longer in patients treated with the study drug (6.9 vs. 1.6 months; HR 0.38; 95% CI: 0.32--0.46; *p* \< 0.001) as well as median OS (13.6 vs. 9.7 months; HR 0.70; 95% CI: 0.57--0.87; *p* \< 0.001). In patients treated with vemurafenib, adverse cutaneous skin carcinoma, keratoacanthoma and skin papilloma were noted respectively in 19%, 11% and 28% of patients \[[@CIT0001]\].

James Larkin presented results of an open-label, multicenter safety study of vemurafenib in patients with metastatic melanoma. Of 1964 screened patients, 914 were enrolled in the study and 834 evaluable for toxicity analysis. 70% of patients received prior systemic treatment due to metastatic melanoma (14% -- ipilimumab, 2% -- MEK and BRAF inhibitors). Adverse events (AEs) were observed in 66% of patients (88% were related to vemurafenib). The most frequently observed any grade AEs were arthralgia (31%), rash (29%), fatigue (22%), photosensitivity (21%) and nausea (15%). Grade 3 and 4 AEs occurred respectively in 33% and 1.9%. The most common were rash (3.6%), arthralgia (3.1%) and cutaneous cell carcinoma/keratoacanthoma (4.3%). In 6% of patients treatment was discontinued due to AEs (mainly arthritis and abdominal pain). At the time of study analysis 302 patients were evaluable for tumor assessment at week 8 of treatment; 61% developed objective responses, and 29% stable disease (SD) \[[@CIT0002]\].

Another active BRAF kinase inhibitor in the treatment of metastatic melanoma patients is dabrafenib (GSK2118436). Results of a randomized, open-label, multicenter phase 3 study (BREAK-3) comparing the efficacy of dabrafenib and DTIC in patients with BRAF V600E mutated metastatic melanoma were presented at the meeting. The study enrolled 250 previously untreated patients. In one study arm patients received oral dabrafenib at a dose of 150 mg twice a day. In the second arm DTIC at a dose of 1000 mg/m^2^ was administered in three-week intervals. 31% of patients presented greater than 1 ECOG performance status and 66% of enrolled patients had stage M1c melanoma. The objective response rate was superior in patients treated with dabrafenib -- 53% vs. 19%. Patients treated with the study drug also demonstrated longer median PFS -- 5.1 vs. 2.7 months (HR 0.30; 95% CI: 0.18--0.53; *p* \< 0.0001). The OS data were immature at this point for the study analysis. The most frequent adverse events observed in patients treated with dabrafenib were hyperkeratosis (37%), headache (32%), pyrexia (28%), arthralgia (27%) and skin papillomas (24%). Serious adverse events (SAEs) included pyrexia (6%), squamous cell carcinoma (6%) and new primary melanoma (2%) \[[@CIT0003]\].

A number of clinical trials showed low efficacy of anti-cancer agents in melanoma patients with brain metastases. However, small molecules have demonstrated some efficacy in patients with solid tumors with concomitant brain metastases. Dabrafenib in a phase 2 study (BREAK-MB) in patients with BRAF V600E/K mutation with intracranial lesions demonstrated high clinical efficacy. The study enrolled stage IV melanoma patients with ≥ 1 intracranial metastases. 127 patients were recruited to one of the two study arms, but only 41 patients reached 8-week disease assessment at the time of interim analysis. Patients in cohort A did not receive any prior brain metastasis treatment before entering the trial. Patients in group B before enrolment developed intracranial progression following prior brain therapy. Unconfirmed overall intracranial response rate (OIRR) was 53% in patients with BRAF V600E mutant in both study cohorts. The unconfirmed OIRR in patients with BRAF V600K mutation was 20% and 50%, respectively, in arms A and B. These preliminary results confirm efficacy of dabrafenib in melanoma patients with intra- and extracranial metastases with acceptable toxicity \[[@CIT0004]\].

Trametinib is a reversible, highly selective allosteric inhibitor of MEK 1/2 activation and kinase activity. Results of a phase 3 (METRIC) study comparing trametinib with chemotherapy in patients with BRAF V600/K mutant advanced or metastatic melanoma were presented at the ASCO conference. 273 patients were randomized in a 2 : 1 ratio to receive trametinib or paclitaxel/DTIC. Patients with disease progression after chemotherapy were allowed to cross over to the trametinib arm. The overall response rate observed in the study drug arm was 24% compared with 7% in patients treated with chemotherapy. In the group receiving trametinib the median PFS was greater than in the control arm -- 4.8 vs. 1.4 months (HR 0.44; 95% CI: 0.31--0.64; *p* \< 0.0001). Analysis of OS demonstrated that 81% of patients in the trametinib group were alive after 6 months of follow-up, compared with 67% in the chemotherapy group (HR 0.53; 95% CI: 0.30--0.94, *p* \< 0.01). The most common adverse events observed in patients treated with trametinib were skin rash, diarrhea, edema, hypertension and fatigue. Typical adverse events connected with MEK inhibitor treatment included chorioretinopathy (\< 1%) and decreased ejection fraction (7%) \[[@CIT0005]\].

Jeffrey Weber has presented encouraging results of a phase I/II study presenting safety and efficacy of dabrafenib combined with trametinib in BRAF V600 mutant metastatic melanoma patients. The trial enrolled 77 patients. The overall response rate observed in the study was 56% with 4 CR, 39 PR, 29 SD and 3 PD. Overall PFS was 7.4 months. The most frequently noted SAEs were pyrexia (6.5%), fatigue (6.5%) and dehydration (6.5%). The combination of dabrafenib and trametinib was associated with a lower incidence of MEK inhibitor related rash and BRAF inhibitor induced hyperproliferative skin lesions when compared to the single agents. Skin toxicity over grade 2 occurred only in 2% of patients. Cutaneous squamous cell carcinoma and keratoacanthoma were observed in 2% of patients \[[@CIT0006]\].

Encouraging results of a Chinese phase II trial comparing first line treatment of rh-endostatin (angiogenesis inhibitor) plus DTIC with DTIC alone in patients with advanced melanoma have been presented. The study enrolled 110 patients. Patients treated with rh-endostatin plus DTIC showed longer PFS -- 5.0 vs. 1.5 months (95% CI: 2.45--7.55; *p* = 0.004) and longer OS -- 16 vs. 7 months (95% CI: 10.46--21.54; *p* = 0.003). However, no statistical difference in overall response rate between study groups was noted. Treatment with rh-endostatin combined with DTIC was well tolerated, with grade 3--4 toxicity (mainly elevated transaminase and thrombocytopenia) observed only in 1.7% of patients \[[@CIT0007]\].

A new agent, cabozantinib, has been tested in a randomized phase II trial in patients with metastatic cutaneous/mucosal (70%) and ocular (30%) melanoma. Cabozantinib is an MET and VEGFR2 inhibitor. The study randomized 77 previously treated patients with a known BRAF mutation in 32%. An objective response was observed in 60% of patients. Progression-free survival was longer in patients treated with cabozantinib -- 5.7 vs. 3.0 months (HR = 0.3; *p* = 0.055). Toxicity of the study drug was comparable to that of other VEGFR (vascular endothelial growth factor receptor) TKIs (tyrosine kinase inhibitors) \[[@CIT0008]\].

Interim analysis of a single arm phase II trial assessing another VEGFR TKI, pazopanib, and paclitaxel in first-line treatment for unresectable stage III and IV melanoma demonstrated a 48% overall response rate. Disease control (PR + + SD) was seen in 80% of patients. Grade 3 and 4 hypertension was observed in 28%, transaminitis in 21%, neutropenia in 14% of patients \[[@CIT0009]\].

Studies of mTOR (mammalian target of rapamycin kinase) inhibitors in two small phase II studies demonstrated efficacy. In one trial in advanced melanoma patients temsirolimus was combined with bevacizumab and showed PR in 19% and SD in 56% of patients; the most notable responses were seen in patients with BRAF wild type tumors \[[@CIT0010]\]. Another trial enrolled metastatic melanoma patients to evaluate the combination of everolimus with paclitaxel and carboplatin. Partial response was observed in 17% and SD in 60% of patients \[[@CIT0011]\].

Immunotherapy {#S0002}
=============

Ipilimumab is a fully human monoclonal antibody (mAb) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Currently ipilimumab and vemurafenib are the only two new drugs approved for the treatment of metastatic melanoma. Ipilimumab's first approval was in the U.S. (2010) and subsequently in Europe (2011) in the second line treatment after failure of chemotherapy (MDX010-20 study). Ipilimumab is also accepted in the U.S. (2010) in previously untreated patients with metastatic melanoma.

During the ASCO meeting Omid Hamid presented the results of the ipilimumab U.S. expanded access program (EAP) in patients with unresectable stage III or IV melanoma. The study also enrolled patients with brain metastases (27%), ocular melanoma (5%) and mucosal melanoma (4%). 906 patients were treated with ipilimumab in a dose of 10 mg/kg every 3 weeks (4 doses -- induction phase) followed by 10 mg/ kg every 12 weeks (maintenance phase) until progression or unacceptable/unmanageable toxicity of the treatment. Durable OS over 3 years was observed in 17% of patients. Drug-related SAEs were noted in 27%. The most common were diarrhea (10%), colitis (8%), endocrinopathies (4%), and dermatitis (0.8%). Incidence of SAEs such as hepatitis (0.24%), intestinal perforations (0.36%) and drug-related death (0.24%) was consistent with that seen in other trials evaluating 10 mg/kg ipilimumab monotherapy. 11% of patients discontinued treatment due to drug toxicity \[[@CIT0012]\].

Currently a phase I/II trial evaluating ipilimumab in combination with vemurafenib is ongoing with the first enrolled metastatic melanoma (BRAF V600 mutant) patient in November 2011 \[[@CIT0013]\].

Paul Chapman's group demonstrated interesting results of hypersensitivity skin reactions in melanoma patients treated with vemurafenib after previous ipilimumab therapy. The investigators observed drug-related rash associated with vemurafenib in 13 out of 16 treated patients (81%). Four patients developed grade 3 maculopapular rash which occurred within 8 days of starting the vemurafenib treatment. Biopsies demonstrated spongiotic and perivascular dermatitis with eosinophils consistent with a drug hypersensitivity reaction. They did not progress to life-threatening reactions such as anaphylaxis or Stevens-Johnson syndrome and did not necessitate discontinuation of vemurafenib treatment. The incidence of grade 3 rash was higher than that observed in patients treated with vemurafenib in the phase III BRIM3 trial (25% vs. 8%; *p* = 0.02) \[[@CIT0014]\].

Ipilimumab has also shown some activity in patients with metastatic melanoma and brain metastases, particularly when metastases were small and asymptomatic. Results of a phase 2 study of these patients were published recently in *Lancet Oncology*. The intracranial response rate was 24% (patients neurologically asymptomatic without corticosteroid treatment) and 10% (patients with neurological symptoms on a stable dose of corticosteroids) \[[@CIT0015]\]. Activity of ipilimumab and fotemustine in metastatic melanoma patients has been tested in the NIBIT-M1 trial. 86 patients with asymptomatic brain metastases were enrolled in the study (7 patients had prior whole brain radiotherapy or radiosurgery). Patients received 4 doses of ipilimumab 10 mg/kg every 3 weeks plus fotemustine 100 mg/m^2^ weekly for 3 weeks, followed by ipilimumab every 12 weeks (from week 24) combined with fotemustine every 3 weeks (from week 9). The immune related (ir) disease control rate (irDCR = CR + PR + + SD using the ir response criteria) was 50% and immune related overall response rate (irORR = CR + PR) was 40%. Median irPFS was 4.6 months and 1-year OS was 52%. Median OS was not reached at the time of study analysis. Grade 3 or 4 toxicity was observed in 60% of patients (hematological toxicity -- 50%, elevated ALT/AST -- 5%, gastrointestinal adverse events -- 5%) \[[@CIT0016]\].

Another trial evaluated the development of brain metastases in metastatic melanoma patients treated with ipilimumab and temozolomide. Of 64 enrolled patients (2 with a history of prior brain metastases), 11 (17%) developed brain metastases at a median follow-up of 41 weeks. The median time to brain metastases expansion was 12 weeks \[[@CIT0017]\].

A new interesting anti-cancer agent is anti-PD-1 (BMS-936558, MDX-1106), a fully human mAb that blocks the programmed death-1 (PD-1) co-inhibitory receptor expressed by activated T-cells. BMS-936558 was evaluated in 95 previously treated metastatic melanoma patients. The study drug was administered intravenously every 2 weeks until PD or CR, for a maximum of 12 cycles. The doses varied depending on the study cohort (0.1--10 mg/kg). SAEs occurred in 19% of patients. The most common included gastrointestinal (4%), endocrine (2%) and hepatobiliary disorders (1%). The observed response rate was 20--41% depending on the study cohort. Of the 20 patients that responded to the treatment, 12 developed a response lasting over 1 year. Currently further evaluation of BMS-936558 is ongoing \[[@CIT0018]\]. BMS-936558 was also evaluated in combination with a multipeptide vaccine in a phase I study in 30 previously treated patients with metastatic melanoma. Patients were vaccinated with MART-1/gp100/NY-ESO-1 peptides with adjuvant Montanide ISA 51 together with BMS-936558 (1, 3 or 10 mg/kg) every 2 weeks for 24 weeks, followed by BMS-936558 alone every 3 months. Responses to the treatment were observed in all study cohorts (1/3/10 mg/kg -- 2 PR/5 PR/2 PR and 1 SD). Immunological tests demonstrated decreased PD-1 receptor on CD4+ and CD8+ lymphocytes and increased CTLA4 receptors, and a dose-related decrease in CD8 T-cells while CD4 T-cells increased \[[@CIT0019]\].

Investigators from Russia presented results of a trial evaluating efficacy of a dendritic cell (DC)-based vaccine in patients with high risk resected melanoma (stage III and IV). 108 patients were enrolled in the trial. In one study arm 56 patients (stage III -- 46, IV -- 10) were treated with autologous monocyte-derived DC vaccine primed with autologous tumor lysate, administered intradermally every 2--6 weeks until disease progression. In the control group 53 patients (stage III -- 47, IV -- 5) underwent observation. At a median follow-up of 22 months disease-free survival (DFS) was significantly longer in patients treated with the vaccine (HR 0.45; 95% CI: 0.29--0.69; *p* \< 0.05) although there was no difference in OS between the study arms (HR 0.71; 95% CI: 0.40--1.25*; p* = 0.23). 60% of vaccinated patients remained alive at the time of study analysis. The investigators observed a significant correlation between reduction of risk and vaccine-induced strong delayed type hypersensitivity reaction. The vaccine was safe and well tolerated \[[@CIT0020]\].

At the ASCO meeting investigators reported on a phase 3 trial (OPTiM) evaluating effectiveness of intratumoral injections of talimogene laherparepvec (T-VEC) compared with subcutaneous administration of GM-CSF (granulocyte-macrophage colony-stimulating factor) in patients with advanced and metastatic melanoma. T-VEC (formally OncoVEX^GM-SCF^) is an oncolytic HSV1 that selectively replicates in tumors inducing a systemic anti-tumor immune response enhanced by local GM-SCF expression. Results of this trial are expected later in 2012 \[[@CIT0021]\].

An interesting strategy consisting of CD40 ligand/interferon-γ matured autologous DC immunized with gp100 antigen HLA (human leukocyte antigen) I restricted peptides in patients with metastatic melanoma has been shown. Out of 7 treated patients 2 PR were noted and 1 CR with a duration of over 3 years. 6 patients developed CD8+ T cell immunity to gp100. The investigators demonstrated a significant correlation of IL-12 production by DCs with TTP (time to progression) \[[@CIT0022]\]. Other early phase immunotherapy trials included: intra-lesional administration of TG1042 (adenovirus expressing interferon-gamma) combined with adoptive TIL (tumor infiltrating lymphocytes) transfer \[[@CIT0023]\]; TCR-IL-2 (T-cell receptor-interleukin-2) fusion protein in combination with cisplatin \[[@CIT0024]\]; HyperAcute-Melanoma vaccine combined with pegylated interferon \[[@CIT0025]\]; and autologous TIL infusion combined with lymphodepleting chemotherapy and low-dose IL-2 \[[@CIT0026]\].
